Scotiabank Reiterates Outperform Rating for Arcellx (NASDAQ:ACLX)

Scotiabank reissued their outperform rating on shares of Arcellx (NASDAQ:ACLX – Free Report) in a report published on Thursday morning, Stock Target Advisor reports. Scotiabank currently has a $82.00 price objective on the stock. ACLX has been the topic of a number of other research reports. Barclays increased their target price on Arcellx from $62.00 […]

Related Keywords

United States ,Switzerland ,China ,Swiss ,Christopher Heery ,Michelle Gilson ,Suvretta Capital Management ,Swiss National Bank ,Vivo Capital ,China Universal Asset Management Co ,Securities Exchange Commission ,Morgan Stanley ,Scotiabank ,Canaccord Genuity Group ,Rafferty Asset Management ,Needham Company ,Arcellx Inc ,Barclays ,Free Report ,Stock Target Advisor ,Genuity Group ,Get Free Report ,Exchange Commission ,Asset Management ,Capital Management ,Universal Asset Management ,National Bank ,Arcellx Daily ,Arcellx ,Nasdaq Aclx ,Aclx ,Medical ,Reiterated Rating ,